Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
<p>Percentage change in Ki67 between pretreatment (baseline) and surgery for part 1 (<b>A</b>) and part 2 (<b>B</b>); Kaplan–Meier estimates by treatment group for relapse free survival (<b>C</b>) and overall survival (<b>D</b>). <b>A,</...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | , , , , , , , , , , , , , , , , , , , , , |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
| Crynodeb: | <p>Percentage change in Ki67 between pretreatment (baseline) and surgery for part 1 (<b>A</b>) and part 2 (<b>B</b>); Kaplan–Meier estimates by treatment group for relapse free survival (<b>C</b>) and overall survival (<b>D</b>). <b>A,</b> Waterfall plots for part 1 and part 2: for each patient, bar height represents percentage change at surgery from baseline. Percentage change was calculated as [(surgery score + 0.1) − (pretreatment score + 0.1)]/[(pretreatment score + 0.1)]*100. The constant of 0.1 was added to accommodate cases with a value of 0%. Negative values represent decrease from baseline, positive values represent increase from baseline. pCR in breast: patients with pCR (no disease in ether breast or nodes) plus two additional patients with 0% breast cellularity but nodal involvement are represented as bars of height −120% at the left of the figures and noted “pCR in breast;” any existing Ki67 values for these patients have been excluded of the main analysis; in a sensitivity analysis, we imputed a value of −100% change for these patients (Appendix 2). Small triangles indicate patients with RCB1. Disease recurrences are also indicated at the top of each figure with circles and crosses. <b>B,</b> RFS is represented in the time interval of up to 6 years after randomization, as no RFS event occurred later. Overall survival is represented in the fully observed range of values. Log-rank test comparing concurrently randomized treatment groups are reported in the figures. In the figure, trastuzumab and control part 1 and part 2 groups are combined to improve readability. C, control; L, lapatinib; T, trastuzumab; T+L, combination; P1, part 1; P2, part 2; all, P1&P2; <i>P</i>, <i>P</i> value.</p> |
|---|